[Therapeutic experiences in the treatment of hyperlipoproteinaemia with etofylline clofibrate (author's transl)].
Efficacy and tolerance of 1-(theophyllin-7-yl)-ethyl-2-[2-(p-chlorophenoxy)-2-methylpropionate] (etofylline clofibrate, Duolip) was investigated in 100 patients under practitioner conditions, out of whom 50 patients received daily 500 mg (2 x 1 capsule etofylline clofibrate and 50 patients daily 750 mg (3 x 1 capsule) over a therapeutic period of 8 weeks each. The whole group consisted of patients of type IIa, IIb and IV. The effect on blood lipids was determined in the parameters cholesterol, triglycerides and total-beta-lipoproteins. In patients of type II high and significant reduction of cholesterol and of total-beta-lipoproteins (27%) were found, in type IV especially significant reductions of triglycerides and total-beta-lipoproteins of 37 and 24%, resp. The rate of responders in type II was between 50 and 100%. Common blood parameters of tolerance did not show remarkable alterations. Unspecific gastrointestinal side effects were only observed in 3 patients. For the therapy of hypolipoproteinaemia etofylline clofibrate was established as a highly active, low-dosed drug.
D002994:Clofibrate / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000188:drug therapy; D006953:Hyperlipoproteinemia Type IV / Q000188:drug therapy; D006951:Hyperlipoproteinemias / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000008:administration & dosage / Q000627:therapeutic use*
D000960:Hypolipidemic Agents; C028764:etofylline clofibrate; D002994:Clofibrate
Therapeutische Erfahrungen bei der Behandlung der Hyperlipoproteinämie mit Etofyllinclofibrat.